Bladder Cancer | Tumor

Front-line Bavencio Maintenance Improves Survival Regardless of Primary Tumor Site, Advanced Disease Type in Advanced Bladder Cancer

June 7th 2021, 5:00pm


The study’s lead author noted that the data support giving patients with advanced bladder cancer chemotherapy to get control of the disease and then maintaining that control with maintenance Bavencio.

YouTube May Provide Misleading Information About Bladder Cancer

May 25th 2021, 6:00pm


Some of the most popular YouTube videos about bladder cancer are of poor quality, spread misinformation and have commercial bias.

The Cancer Diagnosis That Seemed to Make Little Sense

May 24th 2021, 4:00pm


A retirement counselor with bladder cancer shares the story of his diagnosis and his thoughts on treatment.

News and Updates for Bladder Cancer Awareness Month

May 13th 2021, 1:00pm


A roundup of some of CURE®’s latest news and updates for patients with bladder cancer in honor of Bladder Cancer Awareness Month this May.

FDA Panel Votes in Favor of Upholding Tecentriq’s Indication in First-Line Treatment of Bladder Cancer

May 5th 2021, 9:00pm


FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.

A Cancer Research Writer Turns His Pain Into Hope For Others

April 22nd 2021, 3:00pm


In this episode of the “CURE® Talks Cancer” podcast, Henry Scowcroft discusses his experiences writing a book about his late wife’s cancer journey and offers advice for other caregivers.

Almost 5% of Patients Undergo Incomplete Procedure to Remove Kidney and Nearby Tissue for Upper Tract Urothelial Carcinoma

April 13th 2021, 9:00pm


Several factors were associated with patients undergoing radical nephrectomy compared with radical nephroureterectomy including Black race, large tumors, advanced tumor stage and high-grade tumors.

FDA Grants Accelerated Approval to Trodelvy for Advanced Bladder Cancer

April 13th 2021, 7:37pm


Trodelvy has received accelerated approval from the FDA for the treatment of patients with advanced urothelial cancer.

Adjusted-Dose Combination Therapy May Address Needs of Patients with Urothelial Carcinoma Unable to Tolerate Cisplatin Treatment

April 12th 2021, 9:00pm


Adjusting the dose of cisplatin, when added to regular doses of Abraxane and gemcitabine, led to similar survival rates when treating patients with advanced/metastatic urothelial carcinoma, which may help to address issues commonly seen with patients who cannot tolerate cisplatin such as renal dysfunction.

Tecentriq’s Indication for Previously Treated Metastatic Bladder Cancer Pulled by FDA, Manufacturer

March 9th 2021, 2:00pm


If patients were receiving Tecentriq for prior platinum-based treated metastatic urothelial carcinoma, they should discuss next best steps with their health care providers.